Treatment of levodopa-induced motor complications

被引:88
作者
Stocchi, Fabrizio [1 ]
Tauliati, Michele [2 ]
Olanow, C. Warren [2 ]
机构
[1] IRCCS San Raffaele, I-00163 Rome, Italy
[2] Mt Sinai Sch Med, New York, NY USA
关键词
advanced Parkinson's disease; dyskinesias; motor fluctuations; levodopa; dopamine agonists;
D O I
10.1002/mds.22052
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. fit this review. we provide in overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa closing to establish the optimum treatment schedule. improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (NIAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. W highlight the importance of initiating therapy with it treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD. dykinesias, motor fluctuations. levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors. (c) 2008 Movement Disorder Society.
引用
收藏
页码:S599 / S612
页数:14
相关论文
共 155 条
[1]   Levodopa: why the controversy? [J].
Agid, Y ;
Olanow, CW ;
Mizuno, Y .
LANCET, 2002, 360 (9332) :575-575
[2]   Bilateral subthalamotomy in Parkinson's disease: initial and long-term response [J].
Alvarez, L ;
Macias, R ;
Lopez, G ;
Alvarez, E ;
Pavon, N ;
Rodriguez-Oroz, MC ;
Juncos, JL ;
Maragoto, C ;
Guridi, J ;
Litvan, I ;
Tolosa, ES ;
Koller, W ;
Vitek, J ;
DeLong, MR ;
Obeso, JA .
BRAIN, 2005, 128 :570-583
[3]   Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease [J].
Anderson, VC ;
Burchiel, KJ ;
Hogarth, P ;
Favre, J ;
Hammerstad, JP .
ARCHIVES OF NEUROLOGY, 2005, 62 (04) :554-560
[4]  
[Anonymous], 1997, Ann Neurol, V42, P747
[5]   Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease [J].
Antonini, Angelo ;
Poewe, Werner .
LANCET NEUROLOGY, 2007, 6 (09) :826-829
[6]   Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome [J].
Antonini, Angelo ;
Isaias, Ioannis U. ;
Canesi, Margherita ;
Zibetti, Maurizio ;
Mancini, Francesca ;
Manfredi, Luigi ;
Dal Fante, Marco ;
Lopiano, Leonardo ;
Pezzoli, Gianni .
MOVEMENT DISORDERS, 2007, 22 (08) :1145-1149
[7]   Tolcapone and fulminant hepatitis [J].
Assal, F ;
Spahr, L ;
Hadengue, A ;
Rubbici-Brandt, L ;
Burkhard, PR .
LANCET, 1998, 352 (9132) :958-958
[8]   TRANSIENT CARDIAC-ARREST DURING CONTINUOUS INTRAVENOUS-INFUSION OF APOMORPHINE [J].
ATTANASIO, A ;
CAPRIA, A ;
LEGGIADRO, G ;
MICHISANTI, M ;
CANNATA, D ;
STOCCHI, F ;
RUGGIERI, S .
LANCET, 1990, 336 (8726) :1321-1321
[9]   Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[10]   Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease [J].
Bara-Jimenez, W ;
Bibbiani, F ;
Morris, MJ ;
Dimitrova, T ;
Sherzai, A ;
Mouradian, MM ;
Chase, TN .
MOVEMENT DISORDERS, 2005, 20 (08) :932-936